IL-22 Links Inflammation, Diabetes, and Sitagliptin Therapy

IL-22 Links Inflammation, Diabetes, and Sitagliptin Therapy

A recent study conducted by the Mailman School of Public Health at Columbia University has discovered that adults with diabetes who exercise according to guidelines can lower their risk of premature death regardless of the number of hours spent sitting per day. This is the first study to demonstrate that regular exercise can reverse the risks of sitting for long periods, particularly in individuals with diabetes. The results of this study were published in the journal Diabetes Care.

Staying Active Offsets Health Risks of Prolonged Sitting in Diabetes Patients

Staying Active Offsets Health Risks of Prolonged Sitting in Diabetes Patients

A recent study conducted by the Mailman School of Public Health at Columbia University has discovered that adults with diabetes who exercise according to guidelines can lower their risk of premature death regardless of the number of hours spent sitting per day. This is the first study to demonstrate that regular exercise can reverse the risks of sitting for long periods, particularly in individuals with diabetes. The results of this study were published in the journal Diabetes Care.

Merilog Becomes First FDA-Approved Rapid-Acting Insulin Biosimilar for Diabetes Care

Merilog Becomes First FDA-Approved Rapid-Acting Insulin Biosimilar for Diabetes Care

The U.S. Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a Novolog (insulin aspart) biosimilar, for the control of glycemia in adults and pediatric patients with diabetes mellitus. Merilog is the first FDA-approved rapid-acting insulin biosimilar and is available as a 3 mL prefilled pen and a 10 mL multiple-dose vial. Merilog reduces mealtime blood sugar surges, allowing for improved control of diabetes.

SGLT-2 Inhibitors and Left Ventricular Function in Type 2 Diabetes

SGLT-2 Inhibitors and Left Ventricular Function in Type 2 Diabetes

The study, titled “The protective effect of sodium-glucose cotransporter-2 inhibitor on left ventricular global longitudinal strain in patients with type 2 diabetes mellitus according to disease duration,” investigates the impact of SGLT2 inhibitors on heart function in type 2 diabetes patients.